This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
OBJECTIVES Hemorrhagic and thrombotic complications are known obstacles in extracorporeal life support (ECLS), and patients requiring postcardiotomy ECLS are particularly prone. The objective of the study was to characterize incidence, type and clinical relevance of bleeding and thrombotic events on PC-ECLS. METHODS 504 patients receiving PC-ECLS between 2000–2021 at a single center were included in a retrospective analysis. Incidence and type of hemorrhagic and thrombotic complications on PC-ECLS were assessed. Overall survival was compared and perioperative risk factors for bleeding and thrombotic events assessed by binary logistic regression. RESULTS Of 504 patients requiring PC-ECLS, 196 patients(38.9%) had 235 bleeding events (surgical site: n = 135(26.8%); cannulation site: n = 68(13.4%); requiring surgical revision, n = 39(7.7%) cannulation site change: n = 17(3.4%), fatal cannulation site bleeding: n = 4(0.8%); intracranial haemorrhage: n = 11(2.1%); gastrointestinal: n = 8(1.6%); pulmonary: n = 8(1.6%), and intra-abdominal/retroperitoneal: n = 5 (1%)). Overall mortality was higher in patients with major bleeding complications than in patients without bleeding complications (p < 0.0001). 74 patients (14.7%) had 84 thrombotic events (ischaemic stroke n = 39 (7.7%); cannula/circuit thrombosis n = 26 (5.2%); peripheral embolism n = 11 (2.2%), device exchange for hemolysis n = 8 (1.6%)). 246 patients (48.8%) had at least one hemocompatibility-related adverse event. Preoperative dual antiplatelet therapy (adjusted OR: 1.83, 95% CI: 1.063–3.137) and ECLS duration (adjusted OR: 1.14, 95% CI: 1.086–1.197) were identified as independent risk factors for haemorrhage, and prior stroke/transient ischaemic attack (adjusted OR: 1.91, 95% CI: 1.08–3.83) and ECLS duration (adjusted OR: 1.09, 95% CI: 1.04–1.15) were identified as risk factors for thrombotic events. CONCLUSIONS Bleeding complications on ECLS are common and significantly impair survival. Nearly half of patients were affected by any hemocompatibility-related event.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.